BGM0504
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects
BrightGene Bio-Medical Technology Co · Phase 1 · Completed · Enrollment 80
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Cohort 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Cohort 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Cohort 3 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Cohort 4 | Obesity or overweight | n/r | n/r | n/r | n/r |